Antisense Received Full Option Exercise of $5.5 million

Antisense Therapeutics Limited (ASX: ANP) ) has announced that it has received a full Options exercise of $5.5 million by conversion and underwriting of listed options that expired on 19 December 2019.

  • Antisense thanks all option holders who converted their options and welcomes the support of major shareholders.
  • The company also thanked new institutional investors and sophisticated clients of Morgans Corporate Limited (Lead Manager and Underwriter to the Options) who participated in the underwriting.
  • The fund raised to be used for phase IIb clinical trial of AT1102 in DMD.

At AEDT (12:53 PM), the stock was trading at $0.0087, down by 2.247 per cent from the previous close.



All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK